~4 spots leftby Sep 2025

Mini Bronchoalveolar Lavage for Lung Injury

Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: WilliamJanssen
Disqualifiers: Transplantation, Hemoptysis, Bleeding risk, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this observational clinical trial is to learn about the role white blood cells (macrophages) play in lung inflammation in people with Acute Respiratory Distress Syndrome (ARDS). The main questions it aims to answer are: 1. How does the immune system respond to different kinds of lung injury and inflammation and how do those processes differ from each other? 2. What roles do the cells that live in the lungs (macrophages) play in turning off inflammation? How does their role differ from other cells that are called to the lung to help repair injury (recruited macrophages)? 3. Will more frequent testing of lung cell samples help reduce the time it takes to start treatment for ventilator-associated pneumonia (VAP) and therefore reduce the rates of initial therapy failure? Participants will be in the intensive care unit (ICU) on a mechanical ventilator (machine that helps patients breathe) because they have ARDS or are on a mechanical ventilator for some other reason (control group). The following will happen: 1. Participants will be given 100% oxygen through the breathing machine (mechanical ventilator) for 3-5 minutes. This is called pre-oxygenation. 2. A lung specialist (pulmonologist), a member of Dr. Janssen's research team, or respiratory therapist will place small amount of saline into the lung using a long catheter going through the breathing tube. 3. The fluid will be removed with suction and will be sent to the laboratory for testing. 4. This will be repeated two more times over the course of 10 days, or less if participants are taken off of the ventilator. The procedure will be performed no more than three times. 5. Two nasal brushings will be taken from the participants' nose. 6. Approximately 3 tablespoons of blood will be removed by putting a needle into the participants vein. This is the standard method used to obtain blood for tests. A total of 9 tablespoons will be taken for research purposes over the course of this study 7. Data including the participants age, sex, severity of illness, and other medical conditions will be recorded to determine how these can affect the white blood cells. 8. If bacteria are isolated from the fluid in the participants lung, the participants' physician may choose to place the participants on antibiotics to treat an infection. 9. A follow-up phone call may be made by a member of the research team after discharge from the hospital. At this time, the participant may be invited to participate in the Post-ICU clinic at National Jewish Health.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the research team or your doctor.

What data supports the effectiveness of the treatment Non-Bronchoscopic Mini Bronchoalveolar Lavage?

Non-bronchoscopic bronchoalveolar lavage (NB-BAL) has been shown to be a valuable method for obtaining lung samples in children with small airways, providing clinically significant information in 85% of cases without needing more invasive procedures. This suggests that NB-BAL can effectively gather important lung information, which may help in managing lung conditions.12345

Is Mini Bronchoalveolar Lavage safe for humans?

Non-bronchoscopic bronchoalveolar lavage (NB-BAL) has been studied for safety in various groups, including preterm neonates and critically ill children. While generally considered safe, there can be potential effects on breathing and blood flow, especially in patients on mechanical ventilation.25678

How does the mini bronchoalveolar lavage treatment differ from other treatments for lung injury?

Mini bronchoalveolar lavage is unique because it is a non-invasive procedure that uses a sterile, disposable feeding tube to collect lung fluid samples in mechanically ventilated infants, providing a safer and less costly alternative to traditional bronchoscopy, which is not feasible in small infants due to their small airways.124910

Research Team

Eligibility Criteria

This trial is for ICU patients on mechanical ventilation due to ARDS or similar conditions, expected to remain ventilated for at least 48 hours. It's not suitable for those with chronic lung diseases, recent immunosuppressant use, history of organ transplant, severe bleeding risks, a directive against life-sustaining treatment, morbid state with less than 14 days survival expectancy or pregnancy.

Inclusion Criteria

I have given, or my legal representative has given, written consent for the study.
I am between 18 and 85 years old.
I have been admitted to the intensive care unit.
See 1 more

Exclusion Criteria

At significant risk for bleeding (INR > 3 or PTT > 3x normal)
Presence of pneumomediastinum or pneumothorax on recent imaging
Presence of an advanced directive with Do Not Intubate (DNI) status (Do Not Resuscitate (DNR) is acceptable)
See 4 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Observation

Participants undergo procedures to collect lung fluid and nasal brushings for analysis of macrophage activity and bacterial presence.

10 days
3 procedures (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the observational procedures, including a potential follow-up phone call.

2-4 weeks

Treatment Details

Interventions

  • Non-Bronchoscopic Mini Bronchoalveolar Lavage (Other)
Trial OverviewThe study observes how white blood cells in the lungs respond to inflammation from ARDS. Participants undergo non-bronchoscopic mini bronchoalveolar lavage (miniBAL) where saline is introduced and then removed from the lungs via a catheter for analysis. This helps understand immune responses and may expedite pneumonia treatment initiation.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Study Population GroupExperimental Treatment1 Intervention
People in the ICU on mechanical ventilation due to a diagnosis of ARDS or any other diagnosis that requires mechanical ventilation (following surgery, sepsis without lung involvement, seizures)

Find a Clinic Near You

Who Is Running the Clinical Trial?

WilliamJanssen

Lead Sponsor

Trials
1
Recruited
60+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+
Dr. Gary H. Gibbons profile image

Dr. Gary H. Gibbons

National Heart, Lung, and Blood Institute (NHLBI)

Chief Executive Officer since 2012

MD from Harvard Medical School

Dr. James P. Kiley profile image

Dr. James P. Kiley

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer since 2011

MD from University of California, San Francisco

Findings from Research

Saline instillation followed by suctioning in healthy piglets significantly increased the opening pressures of the lungs, indicating a change in lung mechanics that could affect ventilation.
Despite a significant decrease in arterial oxygen levels after the procedure, the values remained within the high normal range, suggesting that while there are effects on lung function, they may be manageable with appropriate recruitment maneuvers and PEEP (positive end-expiratory pressure).
Inflation lung mechanics deteriorates markedly after saline instillation and open endotracheal suctioning in mechanically ventilated healthy piglets.Cunha-Goncalves, D., Perez-de-Sá, V., Ingimarsson, J., et al.[2015]
Non-bronchoscopic bronchoalveolar lavage (NB-BAL) is generally safe and well-tolerated in critically ill mechanically ventilated children, with only 7% experiencing significant immediate complications that required increased support.
While there was no overall significant change in oxygenation index (OI) after the procedure, some patients did experience temporary increases in OI, particularly those with baseline OIs greater than 20, indicating the need for careful monitoring in these cases.
How safe is non-bronchoscopic bronchoalveolar lavage in critically ill mechanically ventilated children?Burmester, M., Mok, Q.[2020]
A new method using a 4F balloon wedge pressure catheter allows for bronchoalveolar lavage (BAL) in children with small artificial airways, making it possible to sample alveolar contents without needing a larger bronchoscope.
In a study of 20 children aged 1 month to 6.5 years, this nonbronchoscopic BAL technique successfully provided valuable clinical information in 85% of cases, avoiding the need for open lung biopsy.
Nonbronchoscopic approach to bronchoalveolar lavage in children with artificial airways.Alpert, BE., O'Sullivan, BP., Panitch, HB.[2019]

References

Inflation lung mechanics deteriorates markedly after saline instillation and open endotracheal suctioning in mechanically ventilated healthy piglets. [2015]
How safe is non-bronchoscopic bronchoalveolar lavage in critically ill mechanically ventilated children? [2020]
Nonbronchoscopic approach to bronchoalveolar lavage in children with artificial airways. [2019]
Effect of exogenous surfactant on Paediatric Bronchoalveolar lavage derived macrophages' cytokine secretion. [2020]
Safety and clinical application of nonbronchoscopic bronchoalveolar lavage in preterm neonates with clinical ventilator-associated pneumonia. [2021]
Adult and paediatric size bronchoscopes for bronchoalveolar lavage in mechanically ventilated patients: yield and side effects. [2019]
Safety and tolerability of nonbronchoscopic lavage in ARDS. [2022]
Efficacy of Bronchoalveolar Lavage as Adjunct Therapy in the Treatment of Neonatal Severe Pneumonia: A Prospective Case-Control Study. [2021]
Bronchoalveolar lavage in children with inflammatory and non inflammatory lung disease. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Nonbronchoscopic bronchoalveolar lavage in mechanically ventilated infants: technique, efficacy, and applications. [2019]